Table 3.

Novel agent–based treatment in newly diagnosed cHL

RegimenPhasenStageMedian age, yCRR, %PFS, %Reference
BV+AVD vs ABVD 3 1334 III-IV 35 vs 37 73 vs 71 83 vs 76.1 at 3 y 72,73 
Nivo→nivo+AVD 2 51 IIB*-IV 37 67† 83 at 21 mo 78,28 
Pem→AVD 2 30 IIB*-IV 30 100‡ 100 at a median follow-up of 22.5 mo 80 
Nivo+AVD concomitant vs sequential§ 2 110 I-II (unfavorable) 26 vs 27 83 vs 84 100 vs 98 at 12 mo 81 
BV+AVD 2 34 I-II* (nonbulky) 36 91 94 at 3 y 74 
ABVD→BV 2 40 I-II* (nonbulky) 29 95 92 at 3 y 75 
RegimenPhasenStageMedian age, yCRR, %PFS, %Reference
BV+AVD vs ABVD 3 1334 III-IV 35 vs 37 73 vs 71 83 vs 76.1 at 3 y 72,73 
Nivo→nivo+AVD 2 51 IIB*-IV 37 67† 83 at 21 mo 78,28 
Pem→AVD 2 30 IIB*-IV 30 100‡ 100 at a median follow-up of 22.5 mo 80 
Nivo+AVD concomitant vs sequential§ 2 110 I-II (unfavorable) 26 vs 27 83 vs 84 100 vs 98 at 12 mo 81 
BV+AVD 2 34 I-II* (nonbulky) 36 91 94 at 3 y 74 
ABVD→BV 2 40 I-II* (nonbulky) 29 95 92 at 3 y 75 

Data represent BV and anti-PD-1 therapies in newly diagnosed cHL.

CRR, complete response rate; DTIC, dacarbazine; Pem, pembrolizumab.

*

Includes unfavorable cHL.

†

CR rate 67% by central review and 80% by investigators.

‡

PET-CR rate was 37% after pembrolizumab monotherapy and 100% after AVD × 2 cycles.

§

Concomitant nivo+AVD received 4 cycles of nivo+AVD; the sequential arm received nivolumab × 4 cycles→nivo+AVD × 2 cycles→AVD × 2 cycles followed by 30 Gy involved-site radiation therapy.

View Large